紫杉醇脂质体联合卡铂治疗晚期卵巢上皮癌的临床分析

Clinical analysis of paclitaxel liposome combined with carboplatin in the treatment of advanced epithelial ovarian cancer

目的研究紫杉醇脂质体联合卡铂方案化疗治疗晚期卵巢上皮癌的临床疗效和毒副作用。方法对经减瘤术后病理组织学确诊的Ⅲ～Ⅳ卵巢上皮癌患者26例,采用紫杉醇脂质体联合卡铂方案化疗,其中紫杉醇脂质体130～175mg/m^2第1天静脉滴注;卡铂300mg/m^2第2天静脉滴注,每21天为1个周期,每2个周期评价1次疗效。结果26例患者完全可以评价疗效,其中完全缓解7例,部分缓解11例,稳定6例,进展3例,总有效率为69.23%,其中Ⅲ期有效率为72.22%,Ⅳ期有效率为62.50%。中位疾病进展时间(MTTP)10个月(5～13个月),无复发生存期5个月。毒副作用主要为骨髓抑制和胃肠道反应。结论紫杉醇脂质体联合卡铂方案治疗晚期卵巢上皮癌近期疗效好,毒副作用可以耐受,值得临床推广使用。

Objective To evaluate the efficacy and toxicity paclitaxel liposome and carboplatin in the treatment of advanced epithelial ovaria cancer. Methods The 26 patients with advanced epithelial ovarian cancer were verified by cytology or pathology. 26 cases of patients The received PC chemotherapy. Paclitaxel liposome 130mg - 175mg/m^2 D1 ivdrip, carboplatin 300mg/m^2 D2 ivdrip. Results All 26 cases were available for objective response, CR 7 cases, PR 11 cases, SD 6 cases, and PD 3 cases. The general response rate was 69.23%. Median TTP were 10 months （5 months -13 months）. The main side effects were bone marrow depression and nausea, vomiting. Conclusion The effect of chemotherapy with paclitaxel liposome and carboplatin to the patient of advanced ovarian cancer was certain, the patients could tolerate the therapy, this regime was worthy to be extended.